ARNA Financial Facts
Interest income: 54KNet loss per share allocable to common stockholders, diluted: -0.05
See Full Income Statement
Commitments and contingencies and subsequent events: 0
Common stock: 24K
See Full Balance Sheet
Arena Pharmaceuticals, Inc. (ARNA) Earnings
|
Expand Research on ARNA
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -6.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -7.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/8/19 |  |
Q119 | $12.10 | $13.89 | -$1.79 | $801.1M | $801.7M | N/A |  | | Details |
8/1/13  |
Q213 | $0.18 | $0.15 | +$0.03 | $68.9M | $57.3M | N/A | | | Details | |
| 5/2/13 |
|
Q113 | $0.09 | $0.11 | -$0.02 | N/A | $50.36M | N/A | | | Details |
| 3/4/13 |
|
Q412 | -$0.10 | -$0.03 | -$0.07 | $1.94M | $21.94M | N/A | | | Details |
| 3/14/17 | Q416 | $0.16 | -$0.08 | +$0.24 | $85.4M | $15.58M | = | | | Details | |
| 11/7/16 |
|
Q316 | -$0.05 | -$0.07 | +$0.02 | $19M | $13.99M | N/A | | | Details |
| 8/5/15 |
|
Q215 | -$0.11 | -$0.14 | +$0.03 | $9.18M | $10.95M | N/A | | | Details |
| 11/3/14 |
|
Q314 | -$0.05 | -$0.12 | +$0.07 | $8.2M | $10.9M | N/A | | | Details |
